The Role of Cardiac Staging in Patients with AL Amyloidosis
A panel of expert oncologists discuss the importance of cardiac staging for patients with AL amyloidosis and its role in guiding overall treatment.
EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis
EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis
EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis
EP: 4.Current Treatment Landscape for AL Amyloidosis
EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis
EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis
EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs
EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement
EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis
EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL
EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis
EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials
EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis
EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis
EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
The conversation emphasizes the critical importance of promptly initiating treatment in patients with light chain (AL) amyloidosis with cardiac involvement, highlighting the significance of cardiac staging based on biomarkers like NT-proBNP and high-sensitivity troponin. The panelists discuss the preference for the European modification of the 3-stage Mayo staging system, focusing on identifying patients at the highest cardiac risk. While acknowledging the utility of the Mayo 2004 staging system, the speakers underscore the evolving landscape with effective treatments, suggesting that the uninvolved free light chains (dFLC) biomarker may be less essential in the current era.
The discussion delves into the unmet medical need within cardiac amyloidosis, emphasizing the challenge of identifying and intervening in patients with stage 2 and 3 cardiac involvement. The urgency of recognizing and addressing these patients before their heart involvement reaches a critical point is emphasized, highlighting the potential for significant improvements in upfront risk, which ultimately impacts survival rates.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
